428 related articles for article (PubMed ID: 28729034)
1. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
3. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
5. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
6. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and survival in AA amyloidosis patients.
Ayar Y; Ersoy A; Oksuz MF; Ocakoglu G; Vuruskan BA; Yildiz A; Isiktas E; Oruc A; Celikci S; Arslan I; Sahin AB; Güllülü M
Rev Bras Reumatol Engl Ed; 2017; 57(6):535-544. PubMed ID: 29173691
[TBL] [Abstract][Full Text] [Related]
8. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
9. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
[TBL] [Abstract][Full Text] [Related]
10. Association of Serum Ig Free Light Chains with Mortality and ESRD among Patients with Nondialysis-Dependent CKD.
Ritchie J; Assi LK; Burmeister A; Hoefield R; Cockwell P; Kalra PA
Clin J Am Soc Nephrol; 2015 May; 10(5):740-9. PubMed ID: 25825483
[TBL] [Abstract][Full Text] [Related]
11. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
12. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
[TBL] [Abstract][Full Text] [Related]
13. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
Decourt A; Gondouin B; Delaroziere JC; Brunet P; Sallée M; Burtey S; Dussol B; Ivanov V; Costello R; Couchoud C; Jourde-Chiche N
Clin J Am Soc Nephrol; 2016 Mar; 11(3):431-41. PubMed ID: 26728585
[TBL] [Abstract][Full Text] [Related]
14. Renal Hypoxia: An Important Prognostic Marker in Patients with Chronic Kidney Disease.
Zhou H; Yang M; Jiang Z; Ding J; Di J; Cui L
Am J Nephrol; 2018; 48(1):46-55. PubMed ID: 30048964
[TBL] [Abstract][Full Text] [Related]
15. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe.
Ryom L; Kirk O; Lundgren JD; Reiss P; Pedersen C; De Wit S; Buzunova S; Gasiorowski J; Gatell JM; Mocroft A;
HIV Med; 2013 Sep; 14(8):503-8. PubMed ID: 23590641
[TBL] [Abstract][Full Text] [Related]
16. CKD stage V in AL amyloidosis: is it too late to treat? Maybe not.
Leung N
Kidney Int; 2017 Dec; 92(6):1321-1322. PubMed ID: 29153137
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
Gertz MA; Leung N; Lacy MQ; Dispenzieri A; Zeldenrust SR; Hayman SR; Buadi FK; Dingli D; Greipp PR; Kumar SK; Lust JA; Rajkumar SV; Russell SJ; Witzig TE
Nephrol Dial Transplant; 2009 Oct; 24(10):3132-7. PubMed ID: 19403931
[TBL] [Abstract][Full Text] [Related]
18. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
19. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
20. Rapid Deterioration of the Renal Function Caused by the Coexistence of Intratubular Amyloidosis and Myeloma Cast Nephropathy.
Kato H; Fujigaki Y; Asakawa S; Yamaguchi Y; Uozaki H; Komatsuda A; Nagata M; Uchida S
Intern Med; 2015; 54(23):3023-8. PubMed ID: 26631886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]